市場調查報告書
商品編碼
1107769
臨床檢驗服務的全球市場:各檢驗室類型,各專門領域,各用途,各地區分析-預測(~2028年)Clinical Laboratory Services Market Forecasts to 2028 - Global Analysis By Laboratory Type (Hospital, Commercial), Specialty (Hematology, Clinical Chemistry), Application, and By Geography |
全球臨床檢驗服務的市場規模,預計2022年達2,195億7,000萬美金,在預測期間內預計以6.7%的年複合成長率成長,2028年達到3,240億1,000萬美元。
本報告提供全球臨床服務市場相關調查分析,市場市場促進因素,阻礙因素,COVID-19影響,各檢驗室類型、服務供應商、專門領域、產品、所有權、用途、地區市場分析,企業簡介等相關資訊。
According to Stratistics MRC, the Global Clinical Laboratory Services Market is accounted for $219.57 billion in 2022 and is expected to reach $324.01 billion by 2028 growing at a CAGR of 6.7% during the forecast period. Clinical laboratory service is to detect and monitor the test results done on specimens from the body like urine or blood of the patient and provide them with appropriate treatment. A clinical laboratory has a crucial role in the healthcare system as it provides a wide range of services, including the diagnosis, treatment, prevention, and management of patients.
The increasing occurrence of targeted diseases, cardiovascular diseases, such as diabetes, high blood pressure, and lipid disorders are caused due to sedentary lifestyle and unhealthy food consumption. As per the World Health Organization (WHO), in 2018, about 1.5 million people died of tuberculosis, and it is one of the top ten causes of death across the globe. The number of people suffering from diabetes has increased from 108 million in 1980 to 422 million in 2014.
Driver:
Rising awareness among people regarding early diagnosis
Early diagnosis of diseases such as cancer, infection, or others can essentially increase the possibilities of effective treatment at the beginning phase. So, it is one of the important public health strategies. Various governments and global associations started various initiatives to generate awareness regarding early diagnosis. Additionally, different emerging ailments have the potential to cause substantial morbidity, mortality, and economic damage. Efforts undertaken by the governments in the prevention of emerging ailments are expected to fuel the market size during the forecast timeline.
Restraint:
Lack of diagnostic tests
Pricing pressure faced by medical services payers and suppliers and procedural shift from lab-based diagnosis to home-based/point-of-care testing procedures is likely to restrain the growth of the market during the forecast period. It would also have a considerable impact on the profit margins due to the additional costs and possible delays in introducing newly developed tests.
Opportunity:
Rising adoption of automated technologies
The rising adoption of automated technologies to improve efficiency and reduce cost is likely to augment the growth of the market. The introduction of accurate and technologically advanced products, such as companion diagnostics, biochips, and microarrays, has bolstered the demand for early disease detection. The key players in the industry are introducing new services in the market to serve the patients, which in turn provide ample opportunities for market growth.
Threat:
Lack of skilled professionals
Testing and diagnostics are troublesome and require trained professionals. In 2020, owing to the COVID-19 pandemic, many healthcare professionals and lab professionals were affected. This generated a huge shortage of lab professionals and it was quite difficult to generate accurate data. Thus, skilled professionals are required by clinical laboratories to flourish in the coming years.
The stand-alone laboratories segment is expected to be the largest during the forecast period
The stand-alone laboratories segment is estimated to have a lucrative growth owing to the increasing pervasiveness of rare genetic disorders positively influencing technologically advanced stand-alone laboratories. Stand-alone laboratories are proficient to perform different genetic disease testing because of accessibility to advanced diagnostics devices for accurate and efficient detection.
The human and tumor genetic testing segment is expected to have the highest CAGR during the forecast period
The human and tumor genetic testing segment is anticipated to witness the fastest CAGR growth during the forecast period owing to the high prevalence of cancer and tumor cases in the population poised to upsurge the industry progression for clinical laboratory tests. Likewise, the availability of analytical instruments quantifies various types of cancer which enables diagnostic decisions and better surgical performance, thereby augmenting the segment growth.
Region with highest share:
North America is projected to hold the largest market share during the forecast period due to the increasing prevalence of chronic diseases, growing healthcare expenditure, technological advancements in clinical testing techniques, favorable regulatory policies, and supportive reimbursement policies. Furthermore, the presence of a large number of laboratories and ease of diagnosis in this region are also driving the market growth
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period due to the rising healthcare expenditure, increasing number of hospitals and clinical diagnostic laboratories in India and China, and strengthening research base for clinical laboratory testing procedures across India, China, and Japan.
Some of the key players profiled in the Clinical Laboratory Services Market include Sonic Healthcare, Viapath, Spectra Laboratories, ACM Global Laboratories, BioReference Laboratories, Quest Diagnostics, Clinical Reference Laboratory, OPKO Health, Inc., NeoGenomics Laboratories, Eurofins Scientific, Labcorp, Fresenius Medical Care, Myriad Genetics, Charles River Laboratories, QIAGEN, Mindray, Bio-Rad Laboratories, Deep Bio, Siemens Healthineers, and Abbott Laboratories.
In March 2022, Mindray launched the new BC-700 Series, a revolutionary hematology analyzer series that incorporates both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests. This series, including two open vial models BC-700/BC-720 and two autoloader models BC-760/BC-780, is designed to empower medium-volume laboratories with advanced diagnostics technologies that are applied in the premium products.
In July 2021, Deep Bio announced a research collaboration agreement with ARUP Laboratories. This Collaboration is benefitted the company in terms of usage of artificial intelligence in diagnostics of cancer. DeepDx® Prostate, Deep Bio's AI-based prostate cancer diagnosis software, will be used for the joint research. This is the first of multiple research projects that ARUP and Deep Bio will collaborate on under the multiyear research program.
Laboratory Types Covered:
Service Providers Covered:
Specialties Covered:
Products Covered:
Ownerships Covered:
Applications Covered:
Regions Covered:
All the customers of this report will be entitled to receive one of the following free customization options:
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.